A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei.

Translated title of the contribution: Results of docetaxel therapy in patients with relapsed ovarian cancer.

Ottó Lehoczky, László Thurzó, Andrea Bagaméri, Zsuzsanna Sárosi, János Udvary, Tamás Pulay

Research output: Contribution to journalArticle

Abstract

Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers. MATERIAL AND METHODS: Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15). RESULTS: CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50% 5 months after the beginning of treatment. CONCLUSION: Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.

Original languageHungarian
Pages (from-to)71-75
Number of pages5
JournalMagyar Onkologia
Volume49
Issue number1
Publication statusPublished - 2005

Fingerprint

docetaxel
Ovarian Neoplasms
Carboplatin
Drug Therapy
Therapeutics
Hungary
Alopecia
Drug Combinations
Area Under Curve
Hypersensitivity
Steroids

ASJC Scopus subject areas

  • Cancer Research

Cite this

Lehoczky, O., Thurzó, L., Bagaméri, A., Sárosi, Z., Udvary, J., & Pulay, T. (2005). A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei. Magyar Onkologia, 49(1), 71-75.

A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei. / Lehoczky, Ottó; Thurzó, László; Bagaméri, Andrea; Sárosi, Zsuzsanna; Udvary, János; Pulay, Tamás.

In: Magyar Onkologia, Vol. 49, No. 1, 2005, p. 71-75.

Research output: Contribution to journalArticle

Lehoczky, O, Thurzó, L, Bagaméri, A, Sárosi, Z, Udvary, J & Pulay, T 2005, 'A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei.', Magyar Onkologia, vol. 49, no. 1, pp. 71-75.
Lehoczky O, Thurzó L, Bagaméri A, Sárosi Z, Udvary J, Pulay T. A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei. Magyar Onkologia. 2005;49(1):71-75.
Lehoczky, Ottó ; Thurzó, László ; Bagaméri, Andrea ; Sárosi, Zsuzsanna ; Udvary, János ; Pulay, Tamás. / A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei. In: Magyar Onkologia. 2005 ; Vol. 49, No. 1. pp. 71-75.
@article{fc8c043818e7497488d4b9763b5df22d,
title = "A ki{\'u}jult petef{\'e}szekr{\'a}kos betegekben alkalmazott docetaxel kezel{\'e}s eredm{\'e}nyei.",
abstract = "Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers. MATERIAL AND METHODS: Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15). RESULTS: CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50{\%} 5 months after the beginning of treatment. CONCLUSION: Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.",
author = "Ott{\'o} Lehoczky and L{\'a}szl{\'o} Thurz{\'o} and Andrea Bagam{\'e}ri and Zsuzsanna S{\'a}rosi and J{\'a}nos Udvary and Tam{\'a}s Pulay",
year = "2005",
language = "Hungarian",
volume = "49",
pages = "71--75",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A kiújult petefészekrákos betegekben alkalmazott docetaxel kezelés eredményei.

AU - Lehoczky, Ottó

AU - Thurzó, László

AU - Bagaméri, Andrea

AU - Sárosi, Zsuzsanna

AU - Udvary, János

AU - Pulay, Tamás

PY - 2005

Y1 - 2005

N2 - Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers. MATERIAL AND METHODS: Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15). RESULTS: CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50% 5 months after the beginning of treatment. CONCLUSION: Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.

AB - Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers. MATERIAL AND METHODS: Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15). RESULTS: CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50% 5 months after the beginning of treatment. CONCLUSION: Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=23944485995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944485995&partnerID=8YFLogxK

M3 - Article

C2 - 15902338

VL - 49

SP - 71

EP - 75

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -